Skip to main content
. 2022 Jul 28;36(9):2242–2249. doi: 10.1038/s41375-022-01648-4

Table 2.

Dynamics of somatic mutations in 100 chronic phase CML patients at diagnosis and after 12, 24, and 36 months of nilotinib therapy.

graphic file with name 41375_2022_1648_Tab1_HTML.gif

(a) Variants detected only at diagnosis or suppressed and subsequently eradicated in follow-up. ASXL1 L775X re-occurred at month 24 in patient #21. Samples with molecular response of at least MMR are shaded in green, no MMR is shaded in red. Low level allele variants (<5% variant allele frequency) are displayed in brackets. n = 19 patients.

(b) Variants detected in every analyzed sample of the respective patient. Samples with molecular response of at least MMR are shaded in green. Low level allele variants (<5% variant allele frequency) are displayed in brackets. n = 5 patients.

(c) Variants detected only in follow-up samples. Samples with molecular response of at least MMR are shaded in green, no MMR is shaded in red. Low level allele variants (<5% variant allele frequency) are displayed in brackets. n = 13 patients.